Published in Vaccine Weekly, July 1st, 2009
EUCODIS Bioscience is developing an innovative protein that LAH plans to use as the active ingredient of a new product line. EUCODIS Bioscience and LAH currently have two development agreements in place. In February, EUCODIS Bioscience announced the achievement of a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2009-07-01)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.